{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Occurrence of one or more adverse events in the participant during the 12-week treatment period","groups":[{"description":"Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg","id":"OG000","title":"Romiplostim"},{"description":"Placebo by subcutaneous injection once weekly","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set, composed of all participants who received at least one dose of study medication","reportingStatus":"POSTED","timeFrame":"12 weeks","title":"Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}